Prescription digital therapeutics startup MedRhythms has entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which aims to improve mobility for people with multiple sclerosis (MS).
Under the deal, MedRhythms would receive a $3 million upfront payment from Biogen, with the potential to earn up to $117.5 million if certain development and commercial...
The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies announced yesterday.
"We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson...
_18.jpg?itok=q487l_qs "Businesspeople shaking hands")
